Biosuperior Technology

BioSuperior Technology is excited to be developing therapeutics for the prevention and treatment of serious lung diseases such as Acute Respiratory Distress Syndrome (ARDS), including SARS-CoV-2 induced illness. Our lead candidate is also expected to treat illness resulting from other lung infections, and following severe smoke inhalation. These expectations are based on a strong understanding of lung biology and data from animal model studies.

Our 1st treatment is for serious lung illness. It is designed to keep patients out of the ICU and prevent long-COVID.
Our drug candidate has worked in animal models. It saves over 50% of animals that have serious lung infection.
Our drug candidate is based on 20 years of scientific research.
We have been awarded $300k from the March of Dimes.
We have patents pertaining to our core technologies: US Patent 8,240,080, and, BioST-002.P2, filed October 16, 2020.
We are collaborating closely with Columbia University and National Jewish Health scientists.
Our team includes 4 scientists with about 100 years of cumulative industrial experience.
Collectively, we have authored 11 patents, 100 peer reviewed publications, and 7 book chapters.

Russ Lehrman, CEO & President
30 yrs + in Pharmaceutical Research and Development. Russ has helped create new drugs for diabetes, Adult Macular Degeneration, and Multiple Sclerosis. He is an Advisor to the Stanford University SPARK Program and co-founder of 2 companies.

Lucia Mokres, VP of Clinical and Regulatory Affairs
Lucia was the Chief Medical Officer of EpiBiome. Prior to that, she Investigated the development of Chronic Lung Disease in premature infants using mouse models of lung development.

Ehud Goldin, VP of Biological Research
An expert biologist who has many cell research discoveries that have helped in the understanding of human health. Ehud has managed human clinical trials relevant to his research.